Cefamandole Lithium | CAS# 58648-57-0 | Antibiotic

MedKoo Cat#: 574455 | Name: Cefamandole Lithium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefamandole Lithium is an analog of Cefamandole -- a broad-spectrum semi-synthetic cephalosporin antibiotic.

Chemical Structure

Cefamandole Lithium

CAS#58648-57-0 (lithium)

Theoretical Analysis

MedKoo Cat#: 574455

Name: Cefamandole Lithium

CAS#: 58648-57-0 (lithium)

Chemical Formula: C18H17LiN6O5S2

Exact Mass: 0.0000

Molecular Weight: 468.43

Elemental Analysis: C, 46.15; H, 3.66; Li, 1.48; N, 17.94; O, 17.08; S, 13.69

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

34444-01-4 (free acid) 58648-57-0 (lithium) 30034-03-8 (sodium)

Synonym

Cefamandole Lithium

IUPAC/Chemical Name

lithium (6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

VLJXYASGGIMGRO-CFOLLTDRSA-M

InChi Code

InChI=1S/C18H18N6O5S2.Li/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9;/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29);/q;+1/p-1/t11-,13-,16-;/m1./s1

SMILES Code

O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O)[O-].[Li+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 468.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sanders CV, Greenberg RN, Marier RL. Cefamandole and cefoxitin. Ann Intern Med. 1985 Jul;103(1):70-8. doi: 10.7326/0003-4819-103-1-70. PMID: 3890658. 2: Csányi P, Hormay M, Radó J. Cefamandol okozta akut veseelégtelenség [Cefamandole-induced acute kidney failure]. Orv Hetil. 1988 Nov 20;129(47):2531-3. Hungarian. PMID: 3057418. 3: Cefamandole and cefoxitin. Med Lett Drugs Ther. 1979 Feb 9;21(3):13-5. PMID: 310945. 4: Greenberg RN, Scalcini MC, Sanders CV, Lewis AC. Cefamandole therapy in anaerobic infections. Antimicrob Agents Chemother. 1979 Mar;15(3):337-41. doi: 10.1128/AAC.15.3.337. PMID: 380458; PMCID: PMC352661. 5: Neu HC, Srinivasan S. Pharmacology of ceftizoxime compared with that of cefamandole. Antimicrob Agents Chemother. 1981 Sep;20(3):366-9. doi: 10.1128/AAC.20.3.366. PMID: 6272631; PMCID: PMC181702. 6: Neu HC. Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis. 1978 May;137 Suppl:S80-S87. doi: 10.1093/infdis/137.supplement.s80. PMID: 650006. 7: Coppens L, Hanson B, Klastersky J. Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother. 1983 Jan;23(1):36-41. doi: 10.1128/AAC.23.1.36. PMID: 6550482; PMCID: PMC184612. 8: Keeton GR, Kehoe B, Phillips SW, Daya H. Ceftazidime and cefamandole in the treatment of pneumonia. J Antimicrob Chemother. 1983 Jul;12 Suppl A:27-30. doi: 10.1093/jac/12.suppl_a.27. PMID: 6352631. 9: Daschner F, Blume E, Langmaack H, Wolfart W. Cefamandole concentrations in pulmonary and subcutaneous tissue. J Antimicrob Chemother. 1979 Jul;5(4):474-5. doi: 10.1093/jac/5.4.474. PMID: 489496. 10: Li Z, Hao J, Chen K, Jiang Q, Wang P, Xing X, Wang J, Zhang Y, Xiao Y, Zhang L. Identification of key pathways and genes in carotid atherosclerosis through bioinformatics analysis of RNA-seq data. Aging (Albany NY). 2021 May 11;13(9):12733-12747. doi: 10.18632/aging.202943. Epub 2021 May 11. PMID: 33973530; PMCID: PMC8148499. 11: Das Gupta V, Stewart KR. Stability of cefamandole nafate and cefoxitin sodium solutions. Am J Hosp Pharm. 1981 Jun;38(6):875-9. PMID: 7246563. 12: Selwyn S. Cefamandole and beta-lactamases. Br Med J. 1978 Jun 10;1(6126):1548-9. doi: 10.1136/bmj.1.6126.1548-a. PMID: 656791; PMCID: PMC1605049. 13: Glatt AE. Second-generation cephalosporins. Hosp Pract (Off Ed). 1986 Mar 15;21(3):158A-158B, 158E, 158H-158L. doi: 10.1080/21548331.1986.11704945. PMID: 3081544. 14: Srinivasan S, Francke EL, Neu HC. Comparative pharmacokinetics of cefoperazone and cefamandole. Antimicrob Agents Chemother. 1981 Feb;19(2):298-301. doi: 10.1128/AAC.19.2.298. PMID: 6214988; PMCID: PMC181413. 15: Wold JS, Turnipseed SA, Broddle WD, Owen NV. Effect of cefamandole nafate on the toxicity of tobramycin. Antimicrob Agents Chemother. 1977 Oct;12(4):465-9. doi: 10.1128/AAC.12.4.465. PMID: 921240; PMCID: PMC429947. 16: Neu HC. Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother. 1974 Aug;6(2):177-82. doi: 10.1128/AAC.6.2.177. PMID: 15828189; PMCID: PMC444624. 17: Rocca B, Mallet MN, Cohade F, Scemama F, Bidet PF, Chevalier A. Antibioprophylaxie par céfamandole en neurochirurgie [Antibioprophylaxis with cefamandole in neurosurgery]. Presse Med. 1989 Jun 10;18(23):1165. French. PMID: 2525749. 18: Conraads VM, Demey HE, Heytens LG, Bossaert LL. Hypoprothrombinemia due to cefamandole. Klin Wochenschr. 1988 Dec 1;66(23):1190-2. doi: 10.1007/BF01727668. PMID: 3062269. 19: Miller WA. Prophylactic cefamandole in orthopaedic surgery. J Bone Joint Surg Am. 1986 Feb;68(2):313. PMID: 3944171. 20: Brogard JM, Kopferschmitt J, Spach MO, Grudet O, Lavillaureix J. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol. 1979 Jul;19(7):366-77. doi: 10.1002/j.1552-4604.1979.tb02493.x. PMID: 479381.